Abstract
Lafora disease is a rare, fatal, autosomal recessive progressive myoclonic epilepsy. The condition is characterised by seizures, myoclonus and dementia. In this case report, a patient who presented with generalised tonic-clonic seizures at the age of 30 is discussed. Until the age of 48, the patient did not have myoclonic jerks or ataxia clinically, but had well controlled seizures. He developed dementia and late extrapyramidal signs. Axillary skin biopsy revealed typical Lafora inclusion bodies. Genetic analysis showed a mutation in the EMP2B gene. To our knowledge, this is the first description of a patient suffering from a Lafora disease without disabling myoclonus and ataxia but rather rare seizures, extrapyramidal signs, and dementia.
Article PDF
Similar content being viewed by others
References
Baykan B, Striano P, Gianotti S, et al. Late-onset and slowprogressing Lafora disease in four siblings with EPM2B mutation. Epilepsia 2005; 46: 1695–1697.
Ganesh S, Delgado-Escueta AV, Suzuki T, et al. Genotypephenotype correlations for EPM2A mutations in Lafora’s progressive myoclonus epilepsy: exon 1 mutations associate with an early-onset cognitive deficit subphenotype.HumMol Genet 2002; 11: 1263–1271.
Guerrero RS, Vernia, Sanz R, et al. A PTG variant contributes to a milder phenotype in Lafora disease. PLoS One 2011; 6: e21294.
Kaufman MA, Dwork AJ, Willson NJ, John S, Liu JD. Lateonset Lafora’s disease with typical intraneuronal inclusions. Neurology 1993; 43: 1246–1248.
Lesca G, Boutry-Kryza N, de Toffol B, et al. Novel mutations in EPM2A and NHLRC1 widen the spectrum of Lafora disease. Epilepsia 2010; 51: 1691–1698.
Minassian BA. Lafora’s disease: towards a clinical, pathologic, and molecular synthesis. Pediatr Neurol 2001; 25: 21–29.
Minassian BA. Progressive myoclonus epilepsy with polyglucosan bodies: Lafora disease. Adv Neurol 2002; 89: 199–210.
Onofrj M, Thomas A, Paci C. Reversible parkinsonism induced by prolonged treatment with valproate. J Neurol 1998; 245: 794–796.
Reutens DC, Puce A, Berkovic SF. Cortical hyperexcitability in progressive myoclonus epilepsy: a study with transcranial magnetic stimulation. Neurology 1993; 43: 186–192.
Ristić AJ, Vojvodić N, Janković S, Sindelić A, Sokić D. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia 2006; 47: 2183–2185.
Shibasaki H. Physiology of negative myoclonus. Adv Neurol 2002; 89: 103–113.
Singh S, Ganesh S. Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum Mutat 2009; 30: 715–723.
Striano P, Ackerley CA, Cervasio M, et al. 22-year-old girl with status epilepticus and progressive neurological symptoms. Brain Pathol 2009; 19: 727–730.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Gökdemir, S., Çağlayan, H., Kızıltan, M. et al. Presentation of an unusual patient with Lafora disease. Epileptic Disord. 14, 94–98 (2012). https://doi.org/10.1684/epd.2012.0489
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/epd.2012.0489